McIlrath & Eck’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

McIlrath & Eck’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$124	Buy	+600	New	+$124	﹤0.01%	1574
2018 Q1	–	Sell	-600	Closed	–	–	567
2017 Q4	$0	Buy	+600	New	–	﹤0.01%	564

Other funds holding NWBO

KFA

Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

McIlrath & Eck's NWBO Position: Q1 2026 in Review

McIlrath & Eck opened a new position in Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2026: 600 shares worth $124. The stake represents ﹤0.01% of the portfolio and ranks #1574 among its holdings. This is a return to the name: McIlrath & Eck previously reported a position in NWBO as recently as Q4 2017.

McIlrath & Eck first reported a position in NWBO in Q4 2017 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold NWBO as of Q1 2026.

McIlrath & Eck held 600 shares of Northwest Biotherapeutics, Inc. Common stock worth $124 as of Q1 2026.
Northwest Biotherapeutics, Inc. Common stock was a new McIlrath & Eck position in Q1 2026.
Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1574 holding.
McIlrath & Eck first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2017 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.